Silence Therapeutics plc (NASDAQ: SLN) reported Q3 EPS of (£0.07), £0.10 better than the analyst estimate of (£0.17). Revenue for the quarter came in at £2.8 million versus the consensus estimate of £2.94 million.

For earnings history and earnings-related data on Silence Therapeutics plc (SLN) click here.